Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMH1UV5)

• Drug Name: REGN5668 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Ovarian cancer	2C73	Phase 1/2	[1]

• Cross-matching ID: TTD Drug ID: DMH1UV5

Molecule-Related Drug Atlas

Drug(s) Targeting Ovarian carcinoma antigen CA125 (MUC16)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Oregovomab	DM06KRC	Ovarian cancer	2C73	Phase 3	[2]
Abagovomab	DMZ0T24	Ovarian cancer	2C73	Phase 2/3	[3]
REGN4018	DM7LOSK	Ovarian cancer	2C73	Phase 1/2	[4]
DMUC-5754A	DMCT4BA	Fallopian tube cancer	2C74	Phase 1	[5]
JCAR020	DM1T8KN	Ovarian cancer	2C73	Phase 1	[6]
PRGN-3005	DMCUE71	Refractory hematologic malignancy	2A85.5	Phase 1	[7]
RG7458	DMW87YE	Ovarian cancer	2C73	Discontinued in Phase 1	[8]

Drug(s) Targeting T-cell-specific surface glycoprotein CD28 (CD28)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Belatacept	DMXLYQF	Kidney transplant rejection	NE84	Approved	[9]
AB-103	DMPDQ8T	Necrotizing soft tissue infection	1B71	Phase 3	[10]
Lulizumab pegol	DMGWZ93	Systemic lupus erythematosus	4A40.0	Phase 2	[11]
REGN5678	DM0Y6WU	Prostate cancer	2C82.0	Phase 1/2	[12]
AU101	DMLAKPI	Osteosarcoma	2B51	Phase 1/2	[6]
SAR442257	DMXD5QP	Malignant neoplasm	2A00-2F9Z	Phase 1	[13]
CD28 and CD137 CAR-T Cells	DMFGQXB	Acute lymphoblastic leukaemia	2A85	Phase 1	[14]
CD19-CAR and CD28-CAR T Cells	DMUR1MN	Acute lymphoblastic leukaemia	2A85	Phase 1	[15]
RO7443904	DMSWZNU	Non-hodgkin lymphoma	2B33.5	Phase 1	[16]
RG6333	DM1BRF2	Non-hodgkin lymphoma	2B33.5	Phase 1	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ovarian carcinoma antigen CA125 (MUC16)	TTC1PS3	MUC16_HUMAN	Not Available	[1]
T-cell-specific surface glycoprotein CD28 (CD28)	TTQ13FT	CD28_HUMAN	Not Available	[1]

References

• [1] ClinicalTrials.gov (NCT04590326) Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3). U.S.National Institutes of Health.
• [2] MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 2014; 13: 129.
• [3] Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer. Immunotherapy. 2011 Feb;3(2):153-62.
• [4] A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. Sci Transl Med. 2019 Jun 19;11(497):eaau7534.
• [5] Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov. 2013 May;12(5):329-32.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Clinical pipeline report, company report or official report of Precigen.
• [8] Phase I clinical trail of RG7458 for treating Ovarian cancer. Genentech Inc.
• [9] New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.
• [13] Clinical pipeline report, company report or official report of Sanofi.
• [14] ClinicalTrials.gov (NCT02186860) Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
• [15] ClinicalTrials.gov (NCT02146924) Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia
• [16] Clinical pipeline report, company report or official report of Genentch
• [17] Clinical pipeline report, company report or official report of Roche